Reducing sodium in a standardized food has not always been a straightforward formulation decision. When a product’s standard of identity specifies salt but does not permit substitutes, changing the ingredient system can create a regulatory barrier as well as a technical challenge. FDA’s final rule, published October 13, 2026, expands the options available to manufacturers by permitting salt substitutes across 139 food standards of identity.
The rule takes effect December 14, 2026. It gives manufacturers more flexibility to replace some or all added salt, but it does not require reformulation or approve a particular substitute. For R&D teams, the opportunity is to explore lower-sodium formulations while establishing whether those formulations still deliver the product characteristics consumers expect.
What the FDA salt substitutes rule changes
Standards of identity define requirements for particular foods, including their ingredients and, in some cases, their manufacturing processes. They help ensure that a food sold under a standardized name has the characteristics consumers associate with it. However, those requirements can also restrict ingredient changes: before this rule, many standards that allowed or required salt did not permit salt substitutes.
The final rule creates a new subpart C, “Flexibility in Standardized Foods,” within 21 CFR part 130. Its ingredient-flexibility provision, § 130.30, establishes a definition of salt substitutes that applies across the affected standards. FDA directly amends 80 standards; another 59 are covered through existing cross-references, bringing the total to 139. That figure refers to standards of identity, not individual products or SKUs.
Affected foods include specified cheeses and cultured dairy products, bread and rolls, self-rising flour, macaroni and noodle products, certain canned fruits and vegetables, tomato juice, canned fish and shellfish, chocolate products, margarine, mayonnaise, and salad dressing. Manufacturers should check the applicable standard rather than assume every product within a broad category is covered.
The change is permission, not a sodium-reduction mandate. Manufacturers can retain their existing formulations, and FDA identifies no regulatory requirement or penalty for choosing not to use the new flexibility.
More ingredient flexibility does not mean fewer safeguards
FDA does not name a fixed list of permitted substitutes. Instead, the rule allows safe and suitable ingredients, or combinations of ingredients, to replace some or all added salt while maintaining the food’s basic nature and essential characteristics. That approach leaves room for different solutions across food categories rather than prescribing one replacement system.
It does not, however, create a new food-additive authorization. An ingredient must still have a lawful basis for its intended use, such as an applicable food-additive approval or generally recognized as safe status under the relevant conditions of use. The rule does not exempt substitutes from those requirements.
For development teams, ingredient selection therefore needs two parallel assessments: whether the proposed use is legally appropriate and whether the substitute performs adequately in the finished product. A supplier’s description of an ingredient as a salt replacement does not resolve either question on its own.
What R&D teams should test before reformulating
Sodium reduction is not simply a matter of changing the salt percentage and recalculating the nutrition panel. Food reformulation can involve trade-offs among taste, texture, and nutritional value. A successful development program needs to evaluate those outcomes together rather than optimize sodium content in isolation.
The following is a suggested development framework, not a testing protocol prescribed by the final rule.
Establish the baseline and the reduction target
Start with the current commercial formula, its sodium contribution by ingredient, and the product’s existing performance specifications. Define what the project is intended to achieve: an incremental sodium reduction, a specific nutritional target, or a formulation that may support a particular label claim.
Keep those objectives separate. FDA explains that the new flexibility addresses limitations in the existing route for modifying standardized foods under § 130.10, which ties certain modifications to nutrient-content-claim requirements. Permission to use a substitute should not be treated as automatic permission to make a “reduced sodium” or “low sodium” claim.
For each trial, record the amount of salt removed, the substitute system added, and any accompanying changes to ingredients or processing. Otherwise, a promising result may be difficult to attribute to the substitution itself.
Assess sensory performance against the existing product
A useful sensory plan should assess more than whether the product tastes salty enough. Include overall flavor balance, aftertaste, aroma, mouthfeel, and acceptance relative to the current formulation.
Use consistent preparation, serving, and evaluation conditions so the team can compare candidates meaningfully. Where practical, evaluate samples without revealing which formulation contains the substitute. Establish acceptance criteria before reviewing results, rather than moving the threshold to accommodate a preferred candidate.
The objective is not necessarily to make every prototype indistinguishable from the original. It is to identify which differences are acceptable for the product, its consumers, and its positioning.
Evaluate texture, processing, and finished-product stability
Choose performance tests that reflect how the product is manufactured and used. Depending on the category, a development plan might examine dough handling and finished-product texture, cheese firmness and melting behavior, or the viscosity and separation behavior of a dressing.
Keep process conditions visible alongside the results. A prototype made successfully under one set of bench conditions is not yet evidence that the formulation will perform consistently at pilot or production scale.
This distinction matters because FDA’s flexibility is intended to support sodium reduction while preserving the basic nature and essential characteristics of standardized foods. Nutritional improvement alone is not the complete development objective.
Build a product-specific safety and shelf-life plan
Include food safety and quality specialists when defining the reformulation study. Ask which existing safety and shelf-life assumptions depend on the current formulation and what evidence is needed to support the proposed change.
Depending on the product and its risk assessment, that review may call for microbiological work, stability studies, packaging assessments, or additional evaluation under intended storage conditions. These should be selected for the product rather than treated as a universal checklist.
Plan the sampling schedule early. A formulation that meets initial sensory and analytical targets still needs to be assessed against the shelf-life requirements the business intends to support.
Confirm nutrient values and review the finished label
Treat nutrition and labeling review as part of development, not as a final packaging task. Once a candidate formula is selected, reconcile ingredient specifications, nutrient calculations, and any analytical results against that exact formula version.
The review should cover the ingredient declaration, sodium and potassium information, applicable allergen declarations, and any proposed nutrient-content claims. Do not assume that a substitute’s commercial name is necessarily the appropriate label declaration or that a lower sodium result automatically supports the intended claim.
The regulatory team should approve the finished label against the applicable requirements before launch. The final rule expands ingredient flexibility; it does not remove manufacturers’ other obligations under food law.
The timeline: an effective date, not a reformulation deadline
The rule’s stated effective date is December 14, 2026. Objections and requests for a hearing concerning the dairy amendments in 21 CFR parts 131 and 133 are due November 12, 2026. FDA also notes that relevant dairy provisions may be stayed through the objection process. Dairy manufacturers should therefore check the status of their applicable provisions before relying on them.
Because adoption is voluntary, manufacturers should distinguish the date the new flexibility becomes available from a deadline to change existing products. There is no requirement to reformulate simply because the rule takes effect.
Keep the evidence connected to the formula
For a manufacturer evaluating substitutes across multiple product lines, each candidate needs more than a formula and a sensory score. It needs a coherent development record: what changed, which batch was tested, how it was processed, what the results showed, and which version was approved.
A practical approach is to give every candidate a controlled formula version and link its ingredient specifications, batch records, sensory evaluations, stability results, and nutrient information to that version. This makes it easier to compare alternatives without losing the conditions behind their performance.
It also creates a clearer handoff between R&D, quality, regulatory, and manufacturing. If the formula changes after testing, the team can identify which results and label inputs need to be reconsidered rather than carrying forward evidence from an earlier prototype.
FDA’s rule creates more room to pursue sodium reduction in standardized foods. A well-designed development program turns that flexibility into a formulation the business can manufacture, substantiate, and release with confidence.
.png)
